Google
PBMWW Stock Price & Analysis — Psyence Biomedical LTD. Warrant
PBMWW FAQ
What is PBMWW's ROE?
Psyence Biomedical LTD. Warrant reports a Return on Equity (ROE) of -212.63%.
What is PBMWW's dividend yield?
Psyence Biomedical LTD. Warrant offers a dividend yield of 0.00%.
What is PBMWW's Quality Score?
Our AI rates PBMWW's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PBMWW?
Our AI Timing Score for PBMWW is 6 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
PBMWW AI Analysis Summary
Our AI summary for PBMWW: Psyence Biomedical LTD. Warrant (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of -212.63%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 6/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.04
Price
0.00
(0.00%)
Day Change
|
|
|---|
PBMWW, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 65 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.04 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
221.507640000000
|
| Average 1W Daily Value |
52.702240000000
GOOD
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 121 Richmond Street West, Toronto, ON, Canada, M5H 2K1
Phone: 416-477-1708
Website: https://psyencebiomed.com
Sector: -
Description: Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
